On January 5, 2022 Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, reported that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will present an overview of the company at the following virtual investor conferences in January (Press release, Candel Therapeutics, JAN 5, 2022, View Source [SID1234598261]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright BioConnect Conference
Format: Pre-recorded corporate presentation
Date/Time: January 10, 2022, on-demand viewing starts at 7:00 am ET
B. Riley Securities’ 2022 Oncology Conference
Format: Live corporate presentation
Date/Time: January 28, 2022, at 11:30 am ET
To access the webcasts or archived recordings of the company presentations, please visit the Candel Therapeutics website at View Source